『Beta Finch - Zoetis - ZTS - EN』のカバーアート

Beta Finch - Zoetis - ZTS - EN

Beta Finch - Zoetis - ZTS - EN

著者： Beta Finch
無料で聴く

AI-powered earnings call analysis for Zoetis (ZTS). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Zoetis Q2 2026 Earnings Analysis

    Zoetis Q2 2026 Earnings Analysis
    2026/08/29
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride.

    ALEX: It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance.

    ALEX: Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset.

    JORDAN: So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments.

    ALEX: Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie.

    JORDAN: Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while.

    ALEX: And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits.

    JORDAN: But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand.

    ALEX: So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack.

    JORDAN: Exactly — that diversification is doing real work for them right now.

    ALEX: Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term.

    JORDAN: It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get.

    ALEX: There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at s

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Zoetis Q1 2026 Earnings Analysis

    Zoetis Q1 2026 Earnings Analysis
    2026/05/07
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    # Beta Finch Podcast Script: Zoetis Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.

    **JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?

    **JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.

    **ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?

    **JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.

    **ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?

    **JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.

    **ALEX:** Let's talk specific numbers. How did their key franchises perform?

    **JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.

    **ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.

    **JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.

    **ALEX:** What about guidance? I imagine they had to adjust expectations.

    **JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit.

    **ALEX:** During the Q&A, there were some pointe

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Zoetis Q4 2025 Earnings Analysis

    Zoetis Q4 2025 Earnings Analysis
    2026/03/21
    **BETA FINCH PODCAST SCRIPT**

    ---

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and I'm here with my co-host Jordan to dive into Zoetis' Q4 2025 earnings call. Jordan, this was quite the earnings report from the animal health giant.

    JORDAN: Absolutely, Alex. But before we jump into the numbers, I need to share an important disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Thanks for that, Jordan. Now, let's talk Zoetis. The company reported some solid numbers for 2025 - $9.5 billion in revenue with 6% organic operational growth, and adjusted net income growing 7% organically. They hit the high end of their November guidance range.

    JORDAN: That's right, and what I found particularly interesting is how their international markets really carried the load here. International delivered 8% organic operational revenue growth while the U.S. was at 4%. It really shows the value of having that global diversification, especially when you're dealing with some headwinds in your home market.

    ALEX: Speaking of headwinds, CEO Kristin Peck was pretty candid about what they're seeing in the U.S. veterinary market. She mentioned economic pressure on Gen Z and millennial pet owners, which has led to declining therapeutic visits. But here's the fascinating part - emergency and urgent care are still showing strength.

    JORDAN: That's such an important distinction, Alex. It's not that pet owners love their animals any less or that underlying demand for care is declining. It's more about price sensitivity and tighter household budgets when it comes to routine care. Pet owners are still bringing their dogs in when they're sick, but they're being more selective about wellness visits.

    ALEX: Exactly. And Peck mentioned that clinics are starting to react by taking a more measured approach to the overall cost of care. The company is responding with targeted actions - optimizing their channel mix, increasing outreach to veterinarians, and reinforcing their scientific leadership through expanded medical education.

    JORDAN: Let's talk about their star performer - the Simparica franchise. This is really impressive stuff. The franchise grew 12% operationally for the year, with Simparica Trio hitting over $1 billion in U.S. sales alone. That makes it their first brand to cross that billion-dollar threshold in the U.S.

    ALEX: And globally, Trio maintained its position as the number one selling canine brand. What I found interesting is their omnichannel strategy - they're seeing double-digit contributions from retail and home delivery channels, which is helping them navigate those headwinds in traditional veterinary clinics.

    JORDAN: That's smart positioning. They're essentially meeting customers where they want to shop, whether that's at the vet, at retail, or having products delivered to their home. It's all about convenience and compliance for pet owners.

    ALEX: Now, let's address the elephant in the room - their OA pain franchise. This declined 3% operationally, with Librela specifically down 6%. This has been a challenge for Zoetis, and there have been some safety concerns raised about these monoclonal antibody treatments.

    JORDAN: Right, but Peck seemed confident about their multipronged strategy to turn this around. She mentioned they're seeing stabilizing monthly sales trends and that veterinarian and pet owner satisfaction remains high. Plus, they're introducing new products like Lanivia and Portela to expand their OA pain portfolio.

    ALEX: The guidance for 2026 is what really caught my attention, Jordan. They're projecting 3% to 5% organic operational revenue growth and 3% to 6% adjusted net income growth. That's a bit more conservative than what we've see

    This episode includes AI-generated content.
    続きを読む 一部表示
    9 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません